SCHEMBL4892497

SCHEMBL4892497

COc1cc(C(=O)Nc2cccc(Nc3nccc(-c4ccc(-n5ccnc5)cc4)n3)c2)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.55
ABL1 P00519 11/20 0.54
BCR P11274 10/20 0.54
PRKCA P17252 7/20 0.54
PDGFRB P09619 6/20 0.54
PDGFRA P16234 6/20 0.54
EGFR P00533 1/20 0.54
PRKCD Q05655 5/20 0.53
SRC P12931 4/20 0.53
PRKD3 O94806 2/20 0.51
PRKCG P05129 2/20 0.51
PRKCB P05771 2/20 0.51
PRKCH P24723 2/20 0.51
PRKCI P41743 2/20 0.51
PRKCE Q02156 2/20 0.51
PRKCQ Q04759 2/20 0.51
PRKCZ Q05513 2/20 0.51
PRKD1 Q15139 2/20 0.51
IKBKB O14920 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903220 0.89 PDGFRA (0.55) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL4903637 0.88 ABL1 (0.71) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4897378 0.86 ABL1 (0.64) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4903263 0.86 ABL1 (0.69) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4897554 0.85 ABL1 (0.72) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4903100 0.84 JAK2 (0.59) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4903186 0.84 ABL1 (0.75) ABL1BCRPRKCAPDGFRBPDGFRA
SCHEMBL4903101 0.84 ABL1 (0.59) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4903381 0.83 ABL1 (0.58) JAK2ABL1BCRPRKCAPDGFRB
SCHEMBL4903369 0.82 ABL1 (0.71) JAK2ABL1BCRPRKCAPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP JAK2 1695/4885ABL1 2843/4885BCR 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.